Figure 2.
Effect of nanobodies on APC anticoagulant activity. (A) Standard curve of Protac-APTT clotting time in PC-depleted plasma diluted in healthy human plasma (o) to achieve a range of PC levels from 0.78% to 100%. The APTT clotting time of healthy human plasma (•) and PC-depleted plasma (∇) in the absence of Protac are also shown. (B) Twenty-one nanobodies were screened at 300 nM in 2 independent experiments (screens 1 and 2). A consistent rank order was observed in the shortening of the Protac-APTT clotting by the 21 nanobodies in both screens. (C) Nanobodies showed a wide variety of effects on the shortening of the Protac-APTT clotting time (duplicates in 2 independent experiments). Among these nanobodies, LP11, LP8, and LP20 exhibited the highest potency to inhibit anticoagulant activity.

Effect of nanobodies on APC anticoagulant activity. (A) Standard curve of Protac-APTT clotting time in PC-depleted plasma diluted in healthy human plasma (o) to achieve a range of PC levels from 0.78% to 100%. The APTT clotting time of healthy human plasma (•) and PC-depleted plasma (∇) in the absence of Protac are also shown. (B) Twenty-one nanobodies were screened at 300 nM in 2 independent experiments (screens 1 and 2). A consistent rank order was observed in the shortening of the Protac-APTT clotting by the 21 nanobodies in both screens. (C) Nanobodies showed a wide variety of effects on the shortening of the Protac-APTT clotting time (duplicates in 2 independent experiments). Among these nanobodies, LP11, LP8, and LP20 exhibited the highest potency to inhibit anticoagulant activity.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal